Goldman Sachs maintained its St. Jude Medical STJ Neutral rating in a research report published today.
In the report, Goldman Sachs states, "St. Jude Medical's annual investor meeting highlighted 18 growth drivers, which should collectively comprise about $8 bn in new market opportunity by 2014, in our view. This compares to the current markets in which St. Jude competes that comprise about $20 bn in total revenues. Including the
new growth drivers, the end-user markets where St. Jude competes will
increase about 60% by 2014."
Shares of St. Jude Medical were at $41.98 in after hours trading at the time of posting, up 0.05% from Friday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in